Sartorius acquires majority stake in ALS Automated Lab Solutions
Sartorius is acquiring a majority stake in ALS Automated Lab Solutions. Sartorius is initially purchasing 62.5% of the shares in ALS as of January 3, 2022. The remaining 37.5% will be acquired in 2026. Read More
Denovo Biopharma announces discovery of novel genetic biomarker
Denovo Biopharma announced that it has discovered a novel genetic biomarker, which it is calling Denovo Genomic Marker 7, using its biomarker discovery platform. Read More
Sosei Heptares enters agreement with Twist Bioscience
Twist Bioscience and Sosei Group have formed a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors identified by Sosei Heptares. Read More
Alpine Immune Sciences, Horizon Therapeutics announce collaboration
Alpine Immune Sciences and Horizon Therapeutics have entered an exclusive license and collaboration agreement to develop and commercialize up to four preclinical candidates generated from Alpine's discovery platform. Read More
Taysha Gene Therapies initiates clinical development of CLN1
Taysha Gene Therapies has initiated clinical development of TSHA-118 for the treatment of classic infantile CLN1 disease. Queen's University in Ontario, Canada, has been selected as the initial clinical site under the direction of Dr. Jagdeep Wahlia, director of research at Queen's University. Read More
Lyell Immunopharma announces FDA clearance of its IND for LYL797
Lyell Immunopharma announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a phase I clinical trial for LYL797. LYL797 is an investigational CAR T-cell therapy for patients with receptor tyrosine kinaselike orphan receptor 1-positive solid tumors. Read More
SK Capital Partners acquires Seqens
SK Capital Partners, a private investment firm, has acquired a majority shareholding in Seqens, which produces active ingredients, pharmaceutical intermediates, and specialty ingredients leveraging 24 industrial sites, 10 R&D centers, and 3,200 employees on three continents. Read More
20n Bio raises $3.3M to advance computational design of protein therapeutics
20n Bio (20n), an artificial intelligence (AI)-powered drug discovery company focused on designing new proteins for therapeutics, has raised a $3.3 million in seed funding. 20n said it will use the proceeds to expand its scientific team, establish a discovery platform, and start multiple early studies in oncology and other genetic diseases. Read More
Carterra, PerkinElmer sign distribution agreement for antibody solutions
Carterra has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer. According to the agreement, PerkinElmer will market, sell, and service Carterra's flagship LSA high-throughput surface plasmon resonance platform and software used for accelerating the discovery of therapeutic antibodies. Read More
Mythic Therapeutics promises improved ADCs, raises $103M
Mythic Therapeutics has raised $103 million in an oversubscribed series B financing round that the company says will help it develop safer, more effective antibody-drug conjugates (ADCs) using its FateControl technology. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
